Zoetis Shares Fall 8% After Earnings Report

Investors remain wary of weak companion animal sales and a cautious 2027 outlook from the animal health company.

Updated on Nov. 11, 2026 in Economic Indicators

Zoetis Shares Fall 8% After Earnings Report

Zoetis shares fell 8% after the company released its fiscal 2026 third-quarter earnings on November 5. Adjusted earnings per share of $1.75 beat analyst expectations of $1.51, though revenue declined 1.3% year over year to $2.39 billion.

Why it matters

The drop reflects investor concern that weakness in the companion animal business is persisting and that the company's 2027 outlook assumes no meaningful recovery in pet-owner spending. Zoetis raised its fiscal 2026 adjusted EPS guidance to $6.25-$6.35, but that did not offset the caution about the coming year.

Zoetis reported adjusted EPS of $1.75, up 2.9% year over year and above the $1.51 analyst estimate, while quarterly revenue of $2.39 billion fell 1.3% year over year. The company raised its fiscal 2026 adjusted EPS guidance to $6.25-$6.35, but the source does not address how the 2027 outlook will change.

The players

Zoetis Inc.

Zoetis is a Parsippany, New Jersey-based animal health company that develops and sells medicines, vaccines and diagnostics for companion animals and livestock.

Jefferies

Jefferies is a global investment banking and securities firm whose equity research analysts cover publicly traded companies, including Zoetis.

The details

Shares fell after investors remained concerned about persistent weakness in the companion animal business and were disappointed by a 2027 outlook that assumes no meaningful recovery in pet-owner spending or competitive conditions. Jefferies downgraded Zoetis to Hold from Buy on October 20 and cut its price target to $83 from $103.

Timeline

  1. October 20, 2026: Jefferies downgraded Zoetis to Hold from Buy and cut its price target to $83 from $103.

  2. November 5, 2026: Zoetis released its fiscal 2026 third-quarter earnings, and shares fell 8%.

Market Dynamics

Zoetis stock has declined 31.2% over the past year while the S&P 500 rose about 10.1%, placing the company's shares sharply behind the broader market. The 8% post-earnings drop extends a trend in which investors have repriced the company's companion animal business amid a cautious outlook.

For investors holding Zoetis, the decline has erased substantial value, with the stock down 34.5% year to date, and the mean analyst price target of $93.57 implies a 13.5% premium to current levels. Shareholders weighing whether to hold or sell should note that the 2027 outlook is the main source of uncertainty cited by investors.

The takeaway

Strong quarterly results can still produce a sharp share decline when forward guidance disappoints. Investors should weigh a company's next-year outlook alongside current earnings beats when assessing a stock.

Further reading

For broader context on market signals, explore Economic Indicators coverage.

Source note: This article includes information reported by Barchart.